Log In
Print
BCIQ
Print
Print this Print this
 

cipargamin (KAE609) (formerly NITD609)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSynthetic spiroindolone analog
Molecular Target P. falciparum P-type cation-transporter ATPase 4 (PfATP4)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMalaria
Indication DetailsTreat malaria
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today